This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-18 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
=== Pharmacodynamics === Pseudoephedrine is a sympathomimetic agent which acts primarily or exclusively by inducing the release of norepinephrine. Hence, it is an indirectly acting sympathomimetic. Some sources state that pseudoephedrine has a mixed mechanism of action consisting of both indirect and direct effects by binding to and acting as an agonist of adrenergic receptors. However, the affinity of pseudoephedrine for adrenergic receptors is described as very low or negligible. Animal studies suggest that the sympathomimetic effects of pseudoephedrine are exclusively due to norepinephrine release.
Acetylcysteine or N-acetylcysteine (NAC) is a mucolytic that is used to treat paracetamol (acetaminophen) overdose and to loosen thick mucus in individuals with chronic bronchopulmonary disorders, such as pneumonia and bronchitis. It has been used to treat lactobezoar in infants. It can be taken intravenously, orally (swallowed by mouth), or by inhalation by use of a nebulizer. It is also sometimes used as a dietary supplement. Common side effects include nausea and vomiting when taken orally. The skin may occasionally become red and itchy with any route of administration. A non-immune type of anaphylaxis may also occur. It appears to be safe in pregnancy. For paracetamol overdose, it works by increasing the level of glutathione, an antioxidant that can neutralize the toxic breakdown products of paracetamol. When inhaled, it acts as a mucolytic by decreasing the thickness of mucus. Acetylcysteine was initially patented in 1960 and came into medical use in 1968. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
Agile Manufacturing is a modern production approach that enables companies to respond swiftly and flexibly to market changes while maintaining quality and cost control. This methodology is designed to create systems that can adapt dynamically to changing customer demands and external factors such as market trends or supply chain disruptions. It is mostly related to lean manufacturing. While Lean Manufacturing focuses primarily on minimizing waste and increasing efficiency, Agile Manufacturing emphasizes adaptability and proactive responses to change. The two approaches are complementary and can be combined into a “leagile” system, which balances cost efficiency with flexibility. The principles of Agile Manufacturing, with its focus on flexibility, responsiveness to change, collaboration, and delivering customer value, serve as a foundation for the later development of Agile Software Development.
The most important isotope for nuclear power applications is uranium-235. It is used in the thermal reactor, and its concentration in natural uranium does not exceed 0.72%. This isotope strongly absorbs thermal neutrons releasing much energy. One fission act of 1 gram of 235U converts into about 1 MW·day. Of importance, is that 23592U emits more neutrons than it absorbs; upon reaching the critical mass, 23592U enters into a self-sustaining chain reaction. Typically, uranium nucleus is divided into two fragments with the release of 2–3 neutrons, for example:
Sources: en.wikipedia.org
=== Compression === Various schemes can be employed to shrink the size of the source data to be stored so that it uses less storage space. Compression is frequently a built-in feature of tape drive hardware.
=== Occurrence === Trace amounts of benzene are found in petroleum and coal. It is a byproduct of the incomplete combustion of many materials. For commercial use, until World War II, much of benzene was obtained as a by-product of coke production (or "coke-oven light oil") for the steel industry. However, in the 1950s, increased demand for benzene, especially from the growing polymers industry, necessitated the production of benzene from petroleum. Today, most benzene comes from the petrochemical industry, with only a small fraction being produced from coal. Benzene has been detected on Mars.
The first was neoprene, a synthetic rubber widely used during World War II. The second was an elastic paste that became very strong upon cooling; this would later become nylon. After these discoveries, Carothers' team was made to shift its research from a more pure research approach investigating general polymerization to a more practically focused goal of finding "one chemical combination that would lend itself to industrial applications". It was not until the beginning of 1935 that a polymer called "polymer 6-6" was finally produced. Carothers' coworker, Washington University alumnus Julian W. Hill had used a cold drawing method to produce a polyester in 1930. This cold drawing method was later used by Carothers in 1935 to fully develop nylon. The first example of nylon (nylon 6.6) was produced on February 28, 1935, at DuPont's research facility at the DuPont Experimental Station. It had all the desired properties of elasticity and strength. However, it also required a complex manufacturing process that would become the basis of industrial production in the future. DuPont obtained a patent for the polymer in September 1938, and quickly achieved a monopoly of the fiber. Carothers died 16 months before the announcement of nylon, therefore he was never able to see his success. The name "Nylon" came from the modification of norun (no run) into a unique name that could be used to market the product but was not trademarked.
The gram-positive bacteria and cyanobacteria that would later give rise to mitochondria and chloroplast found in eukaryotic cells retained the E1 subunits that are genetically related to those found in the BCOADH enzymes.
== History == 1930s – first reports of the use of sucrose for gel electrophoresis; moving-boundary electrophoresis (Tiselius) 1950 – introduction of "zone electrophoresis" (Tiselius); paper electrophoresis 1955 – introduction of starch gels, mediocre separation (Smithies) 1959 – introduction of polyacrylamide gels; discontinuous electrophoresis (Ornstein and Davis); accurate control of parameters such as pore size and stability (Raymond and Weintraub) 1965 – introduction of free-flow electrophoresis (Hannig) 1966 – first use of agar gels 1969 – introduction of denaturing agents especially SDS separation of protein subunit (Weber and Osborn) 1970 – Lämmli separated 28 components of T4 phage using a stacking gel and SDS 1972 – agarose gels with ethidium bromide stain 1975 – 2-dimensional gels (O'Farrell); isoelectric focusing, then SDS gel electrophoresis 1977 – DNA sequencing gels (Sanger) 1981 – introduction of capillary electrophoresis (Jorgenson and Lukacs) 1984 – pulsed-field gel electrophoresis enables separation of large DNA molecules (Schwartz and Cantor) 2004 – introduction of a standardized polymerization time for acrylamide solutions to optimize gel properties with preparative native PAGE A 1959 book on electrophoresis by Milan Bier cites references from the 1800s. However, Oliver Smithies made significant contributions. Bier states: "The method of Smithies ... is finding wide application because of its unique separatory power." Taken in context, Bier clearly implies that Smithies' method is an improvement.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.